Raoua Ben Messaoud

Raoua Ben Messaoud

Auto-generated profile, based on publicly available information

Raoua Ben Messaoud

HP2 Laboratory, INSERM University of Grenoble‐Alpes Grenoble France

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2022 in Sleep Medicine
Verified
Journal Article
Closed access
FMFabrice Monna
Fabrice Monna
RMRaoua Ben Messaoud
Raoua Ben Messaoud
NNNicolas Navarro
Nicolas Navarro
SBSébastien Baillieul
Sébastien Baillieul
LSLionel Sanchez
Lionel Sanchez
JPJean-Louis Pepin
Jean-Louis Pepin

16 April 2022 in SLEEP
Verified
Journal Article
Open access
PDF file
JPJean-Louis Pepin
Jean-Louis Pepin
Sébastien BaillySébastien Bailly
Sébastien Bailly
EMEmmanuel Mignot
Emmanuel Mignot
JGJonathan Gaucher
Jonathan Gaucher
ACAlexandre Chouraki
Alexandre Chouraki
PAPierrick J Arnal
Pierrick J Arnal

9 October 2025 in eClinicalMedicine
Verified
Journal Article
Open access
CFCamille Figard
Camille Figard
RMRaoua Ben Messaoud
Raoua Ben Messaoud
SBSébastien Baillieul
Sébastien Baillieul
MJMarie Joyeux-Faure
Marie Joyeux-Faure
MDMarie Destors
Marie Destors
JPJean-Louis Pepin
Jean-Louis Pepin
Obstructive sleep apnoea (OSA) is a prevalent chronic condition that is associated with cardiometabolic and neurocognitive complications. While continuous positive airway pressure (CPAP) remains the first-line therapy, suboptimal adherence limits its effectiveness, highlighting the need to evaluate alternatives such as mandibular advancement devices (MADs), hypoglossal nerve stimulation (HNS), physical activity, different modalities of weight loss management including glucagon-like peptide-1 (GLP-1) agonists and combination therapies. We conducted an umbrella review to synthesise high-level evidence from meta-analyses of randomised controlled trials (RCTs) evaluating the efficacy, adherence, and safety of therapies used in patients with OSA. A comprehensive search was performed in PubMed, Embase, Web of Science, and the Cochrane Database of Systematic Reviews covering the period from January 1, 2017, to July 5, 2025. Eligible studies were meta-analyses published in English assessing interventions targeting key OSA outcomes, including changes in apnoea–hypopnoea index (AHI), Epworth Sleepiness Scale (ESS), quality of life (QoL), blood pressure (BP), treatment adherence, and safety. When multiple meta-analyses addressed the same intervention-outcome pair, the one including the highest number of RCTs was retained. Two reviewers independently screened studies and extracted data. Methodological quality was assessed using the AMSTAR 2 tool, and the certainty of evidence was evaluated using the GRADE framework. Meta-analyses published in languages other than English, those focusing on paediatric populations or interventions outside the scope of conventional OSA management, and meta-analyses that did not report any of the pre-specified outcomes/interventions of interest were excluded. The review protocol was registered in PROSPERO (CRD42023420729) and the Open Science Framework (https://osf.io/2jvsx). A total of 5571 meta-analyses were identified. Of these, 34 met the inclusion criteria, encompassing 230 RCTs and 36,353 participants (n = 26,058 [72.3%] male). GRADE assessment showed that 12 meta-analyses (35%) had evidence that was of low certainty, 23 (68%) provided moderate-certainty evidence, and only one (3%) provided evidence that was of high certainty. CPAP was the most effective treatment for reducing AHI (mean difference [MD] −30.7 events/h; standardised mean difference [SMD] −1.65, 95% confidence interval [CI] −1.87 to −1.43; low-certainty evidence), followed by GLP-1 receptor agonists (tirzepatide: MD –21.86 events/h; SMD –0.84, 95% CI –1.01 to −0.68; moderate-certainty evidence) and MADs (MD –11.91 events/h; SMD –0.73, 95% CI –14.25 to −9.75; low-certainty evidence). CPAP, wake stimulants, HNS, and myofunctional therapy significantly reduced daytime sleepiness (ESS score SMDs of −0.80 to −0.88; moderate-certainty evidence except for pitolisant and solriamfetol, which were supported by high-certainty evidence). Physical activity led to the greatest improvements in QoL (SMD 1.3, 95% CI 0.58 to 2.02; moderate-certainty evidence), while CPAP also showed modest benefits (SMD 0.16, 95% CI 0.11 to 0.21; critically low-certainty evidence). This umbrella review identified CPAP as the most effective intervention for reducing AHI and daytime sleepiness in patients with OSA, while physical activity yielded the greatest improvements in quality of life. Data on safety, long-term adherence, and combination therapies remain scarce, underscoring the need for more comparative and longitudinal research to support personalised treatment strategies. Data need to be interpreted in the context of several limitations, including those relating to the meta-analysis inclusion criteria and the quality of data in the meta-analyses themselves. None.

25 March 2022 in SLEEP
Verified
Journal Article
Closed access
PDF file
BRBruno REVOL
Bruno REVOL
CCChristel Castelli
Christel Castelli
RMRaoua Ben Messaoud
Raoua Ben Messaoud
ACAmandine Coffy
Amandine Coffy
SBSébastien Bailly
Sébastien Bailly
JPJean-Louis Pepin
Jean-Louis Pepin
Dear Editor, Obstructive sleep apnea (OSA) syndrome corresponds to the repetition of complete or partial collapses of the upper airway during sleep. Its prevalence is high in Europe and North America, varying from 9% to 38% (depending on the study). Approximately 50% of patients with OSA have coexisting hypertension, usually diastolic and nocturnal. The prevalence of OSA is as high as 80% in patients with resistant hypertension [ 1]. Evidence that OSA may be a cause of secondary hypertension includes the high prevalence and incidence of hypertension among patients with OSA, and an observed dose–response effect between the severity of OSA and the likelihood of hypertension. It has been shown that the health costs of patients with OSA are higher than those of individuals without OSA [ 2]. More extensive treatment of OSA would make it possible to reduce the consumption of care and drug usage related to the comorbidities of OSA. Continuous positive airway pressure (CPAP) is considered the gold standard for effective treatment, even if mandibular advancement devices (MAD) are also widely prescribed.

18 October 2026 in Journal of Sleep Research
Verified
Journal Article
Open access
PDF file
FPFran Pilkington-Cheney
Fran Pilkington-Cheney
CAClaire André
Claire André
SUSeren Ucak
Seren Ucak
RMRaoua Ben Messaoud
Raoua Ben Messaoud
ABAnna M. Biller
Anna M. Biller
AMAdriana Michalak
Adriana Michalak
Sleep is fundamental to physical, cognitive, and emotional health and wellbeing. However, it is increasingly threatened by environmental, social, technological, and cultural pressures. To identify key priorities for improving sleep health across Europe, the European Sleep Research Society (ESRS)'s Equality, Diversity and Inclusion Committee (EDIC) and Early Career Network (ECN) convened a joint taskforce to review current challenges and develop strategic recommendations. Through a scoping review of the literature, iterative consensus meetings, and collaborative synthesis, the taskforce identified five overarching challenges: (1) environmental and climate‐related threats to sleep; (2) inequitable access to sleep medicine and care; (3) the rapid expansion and potential of digital health technologies; (4) widespread sleep misinformation and misconceptions surrounding sleep health; and (5) societal change, constant technological connectivity, and the emergence of a 24/7 culture. These interconnected challenges disproportionately affect vulnerable groups and risk exacerbating existing health inequalities. In response, we propose a coordinated set of recommendations structured according to the PESTEL framework (Political, Economic, Sociological, Technological, Environmental and Legal). Collectively, these recommendations advocate for integrated and equity‐focused approaches to strengthen the structural and organisational conditions that support sleep health, improve sleep health literacy, regulate emerging technologies, and ensure that healthy sleep becomes an achievable public health priority across Europe.

2 May 2022
Verified
Conference Paper
Closed access
RMR. Ben Messaoud
R. Ben Messaoud
FMFabrice Monna
Fabrice Monna
NNN. Navarro
N. Navarro
SBSébastien Baillieul
Sébastien Baillieul
CLC. Loiodice
C. Loiodice
JPJean-Louis Pepin
Jean-Louis Pepin